Physician profile
Floyd D Smith
NPI 1437218211
$8,139.31
in general payments reported to CMS, 2019-2025
35 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $1,221 · 2021: $1,551 · 2022: $1,042 · 2023: $1,052 · 2024: $855 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,354.20 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,373.71 | 2019-2025 | Ubrelvy, Qulipta, Viberzi |
| Novo Nordisk INC | $1,342.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $1,054.79 | 2019-2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $1,024.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $397.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $341.29 | 2019-2023 | Camzyos |
| Phathom Pharmaceuticals, INC. | $286.93 | 2024-2025 | Voquezna |
| Pfizer INC. | $258.15 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $241.62 | 2019-2025 | Trintellix |
| Allergan, INC. | $208.19 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.86 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.98 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $125.02 | 2022-2024 | Arexvy |
| Novartis Pharmaceuticals Corporation | $122.28 | 2019-2022 | |
| Amarin Pharma, INC. | $101.83 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $99.70 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $91.61 | 2019-2021 | |
| Amgen INC. | $90.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.64 | 2019-2023 | Trulance, Xifaxan |
| Antares Pharma, INC. | $75.82 | 2019-2022 | |
| Axsome Therapeutics, INC. | $55.69 | 2023-2025 | Sunosi |
| Dexcom, INC. | $44.17 | 2021-2023 | Dexcom G6 Transmitter |
| Braintree Laboratories, INC. | $41.30 | 2020-2021 | |
| Viatris Specialty LLC | $33.80 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $32.22 | 2019 | |
| Abbott Laboratories | $31.01 | 2023 | Freestyle Libre 2 |
| Vanda Pharmaceuticals INC. | $29.52 | 2022 | |
| Azurity Pharmaceuticals, INC. | $28.33 | 2025 | Azmiro |
| Venclose INC. | $24.41 | 2020 | |
| Ironwood Pharmaceuticals, INC | $22.63 | 2020 | |
| Lundbeck LLC | $20.04 | 2023 | Rexulti |
| Medtronic, INC. | $18.99 | 2023 | Venaseal |
| Mylan Specialty L.P. | $18.77 | 2020 | |
| Jazz Pharmaceuticals INC. | $15.66 | 2021 | |
| Corcept Therapeutics | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floyd Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.